These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32292497)

  • 1. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 2. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
    Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
    Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
    Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
    Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
    Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
    Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
    Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
    Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
    Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
    Boot A; Jiang N; Rozen SG
    Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular aspects of upper tract urothelial carcinoma.
    Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
    Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.
    Fang D; Zhang L; Li X; Xiong G; Chen X; Han W; He Z; Zhou L
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):477-85. PubMed ID: 24469253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing characteristics of urothelial carcinoma in kidney transplant recipients between China and Western countries.
    Liu GM; Fang Q; Ma HS; Sun G; Wang XC
    Transplant Proc; 2013; 45(6):2197-202. PubMed ID: 23747184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
    Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational signature and clonal relatedness of recurrent urothelial carcinomas with aristolochic acid.
    Zhu J; Ai Q; Cheng Q; Shen D; Dong Z; Li J; Shen D; Wang W; Zhang X; Li H
    Front Oncol; 2022; 12():990023. PubMed ID: 36185218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
    Rosenquist TA; Grollman AP
    DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
    Hollstein M; Moriya M; Grollman AP; Olivier M
    Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
    Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
    Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure.
    Nortier JL; Schmeiser HH; Muniz Martinez MC; Arlt VM; Vervaet C; Garbar CH; Daelemans P; Vanherweghem JL
    Nephrol Dial Transplant; 2003 Feb; 18(2):426-8. PubMed ID: 12543902
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
    Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X
    BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Level of Aristolochic Acid Detected With a Unique Genomic Landscape Predicts Early UTUC Onset After Renal Transplantation in Taiwan.
    Lai HY; Wu LC; Kong PH; Tsai HH; Chen YT; Cheng YT; Luo HL; Li CF
    Front Oncol; 2021; 11():828314. PubMed ID: 35071023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.